CAS No.: 1222102-29-5
Evogliptin Catalog No. CSN20543
Synonyms: DA-1229
Evogliptin is a potent and selective DPP4 inhibitor (dipeptidyl peptidase 4 inhibitor) which improves insulin resistance and delays the onset of diabetes.
| 规格 | 价格 | 促销价格 | 库存 | 数量 |
|---|
400-920-2911
sales@csnpharm.cn
tech@csnpharm.cn
纯度 & 质量文件
批次:
靶点选择性
生物活性
- 描述
- 临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点 NCT02946541 Type 2 Diabetes Mellitus Phase 3 Completed - Korea, Republic of ... more >> Kangdong Sacred Heart Hospital Seoul, Korea, Republic of, 134-701 Collapse << NCT02753803 Type 2 Diabetes Phase 1 Completed - Korea, Republic of ... more >> Clinical Trials Center, Seoul National University Hospital Seoul, Korea, Republic of, 03080 Collapse << NCT02214693 Renal Impairment Phase 1 Completed - Korea, Republic of ... more >> Clinical Trial Center, Seoul National University Hospital Seoul, Korea, Republic of Collapse << - 更多
- 参考文献
- [1] Kim TE, Lim KS, et al. Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study. Clin Ther. 2012 Sep;34(9):1986-98.
- [2] Kim HJ, Kwak WY, et al. Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3809-12.
实验方案
- 计算器
- 储存液制备
技术信息
| CAS号 | 1222102-29-5 | 储存条件 |
|
|
| 分子式 | C19H26F3N3O3 | 运输 | 蓝冰 | |
| 分子量 | 401.42 | 别名 | DA-1229 |
